¿Por qué sube el precio de la acción de 10X GENOMICS?
Los alcistas dicen
Product adoption
Widespread orders and use of the Atera system by prominent research institutions and major biopharma companies indicate strong commercial interest that could scale the platform's revenue.
Consumables & recurring revenue
Consistent beats in Spatial Biology and Chromium consumables, along with indications of higher consumables per Atera instrument, point to growing recurring revenue that supports revenue stability.
Product roadmap expansion
An expanded roadmap that adds whole‑transcriptome profiling, automation, multiomics, and targeted mutation detection broadens application use cases and can increase the company's addressable market.
Instrument cannibalization
Transition to the Atera platform is reducing demand for existing spatial instruments, which may depress instrument revenue as customers replace legacy systems.
Valuation pressure
Broader peer de‑rating and cautious analyst adjustments have lowered the valuation multiple, which could weigh on the stock despite operational improvements.
Customer adoption uncertainty
Unclear distinction between net new Atera-driven business and replacements, together with limited direct insight from pharmaceutical customers, creates uncertainty about the durability of revenue expansion.



